表紙:多形性膠芽腫(GBM):パイプライン製品の分析
市場調査レポート
商品コード
229730

多形性膠芽腫(GBM):パイプライン製品の分析

Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 2766 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.10円
多形性膠芽腫(GBM):パイプライン製品の分析
出版日: 2020年06月30日
発行: Global Markets Direct
ページ情報: 英文 2766 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

多形性膠芽腫(GBM)は、最も一般的な悪性の原発性脳腫瘍です。GBMはダリア細胞(脳および脊髄内の神経細胞を保護する組織を形成する細胞)から生じます。GBMはアストロサイトとして知られる星状ダリア細胞(膠細胞)で構成されています。兆候と症状は、徐々に進行する神経障害、通常は運動麻痺、頭痛、頭蓋内圧亢進による全身症状(頭痛、悪心、嘔吐、認知障害、発作など)です。治療には、放射線療法、化学療法などが含まれます。

当レポートでは、多形性膠芽腫(GBM)に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

多形性膠芽腫(GBM)の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 未確認段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

治療薬の評価

  • 単独療法の場合
  • 併用療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

図表

List of Tables

List of Tables

  • Number of Products under Development for Glioblastoma Multiforme (GBM), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020 (Contd..1), H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by 1st Bio Therapeutics Inc, H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by 1ST Biotherapeutics Inc, H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by 4D Pharma Plc, H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by Aadi Bioscience Inc, H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by AbbVie Inc, H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by ABM Therapeutics Inc, H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by Accendatech Au Pty Ltd, H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by Actuate Therapeutics Inc, H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by Adastra Pharmaceuticals Inc, H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by Adlai Nortye Biopharma Co Ltd, H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by Aduro BioTech Inc, H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by Advanced Accelerator Applications SA, H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by Advenchen Laboratories LLC, H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by Aettis Inc, H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by Affimed GmbH, H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by Agenus Inc, H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by AiVita Biomedical Inc, H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by Allianz Pharmascience Ltd, H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by Alterity Therapeutics Ltd, H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by Amal Therapeutics SA, H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by MiReven Pty Ltd, H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by Molecular Targeting Technologies Inc, H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by Molecular Templates Inc, H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by Moleculin Biotech LLC, H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by Multimmune GmbH, H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by Mustang Bio Inc, H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by Mycenax Biotech Inc, H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by Nanjing Bioheng Biotech Co Ltd, H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by Nanjing KAEDI Biotech Inc, H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by Nanjing Legend Biotech Co Ltd, H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by Nanomerics Ltd, H1 2020
  • Glioblastoma Multiforme (GBM) - Pipeline by NanoPharmaceuticals LLC, H1 2020

List of Figures

List of Figures

  • Number of Products under Development for Glioblastoma Multiforme (GBM), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
目次
Product Code: GMDHC12327IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme - Pipeline Review, H1 2020, provides an overview of the Glioblastoma Multiforme (Oncology) pipeline landscape.

Glioblastoma also known as glioblastoma multiforme is a fast-growing glioma that develops from star-shaped glial cells that support the health of the nerve cells within the brain. Symptoms include headaches, blurred vision, nausea, vomiting, memory loss, speech difficulty, muscle weakness and loss of appetite. Risk factors include gender (male) and age. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Glioblastoma Multiforme - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Glioblastoma Multiforme (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glioblastoma Multiforme (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 15, 130, 94, 2, 13, 198, 43 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 14, 14, 3, 53 and 9 molecules, respectively.

Glioblastoma Multiforme (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Glioblastoma Multiforme (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Glioblastoma Multiforme (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Glioblastoma Multiforme (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Glioblastoma Multiforme (Oncology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Glioblastoma Multiforme (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Glioblastoma Multiforme (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Glioblastoma Multiforme (GBM) - Overview
  • Glioblastoma Multiforme (GBM) - Therapeutics Development
  • Glioblastoma Multiforme (GBM) - Therapeutics Assessment
  • Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development
  • Glioblastoma Multiforme (GBM) - Drug Profiles
  • Glioblastoma Multiforme (GBM) - Dormant Projects
  • Glioblastoma Multiforme (GBM) - Discontinued Products
  • Glioblastoma Multiforme (GBM) - Product Development Milestones
  • Appendix